Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Petra Obrtlikova"'
Autor:
Alexander Egle, Thomas Melchardt, Petra Obrtlíková, Lukáš Smolej, Tomáš Kozák, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikušková, Liana Gercheva, Thomas Nösslinger, Tomáš Papajík, Miriam Ladická, Michael Girschikofsky, Mikuláš Hrubiško, Ulrich Jäger, Daniela Voskova, Martin Pecherstorfer, Eva Králiková, Christina Burcoveanu, Emil Spasov, Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emília Flochová, Stanislav Palášthy, Olga Stehlíková, Michael Doubek, Petra Altenhofer, Lukas Weiss, Teresa Magnes, Lisa Pleyer, Anton Klingler, Jiří Mayer, Richard Greil
Publikováno v:
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
Abstract No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing i
Externí odkaz:
https://doaj.org/article/5fbc792402b144bb941d23c116493c05
Autor:
Carol Moreno, Marco Montillo, Panayiotis Panayiotidis, Maria Dimou, Adrian Bloor, Jehan Dupuis, Anna Schuh, Stefan Norin, Christian Geisler, Peter Hillmen, Michael Doubek, Marek Trněný, Petra Obrtlikova, Luca Laurenti, Stephan Stilgenbauer, Lukas Smolej, Paolo Ghia, Florence Cymbalista, Ulrich Jaeger, Kostas Stamatopoulos, Niki Stavroyianni, Patrick Carrington, Hamadi Zouabi, Veronique Leblond, Juan C. Gomez-Garcia, Martin Rubio, Roberto Marasca, Gerardo Musuraca, Luigi Rigacci, Lucia Farina, Rossella Paolini, Sarka Pospisilova, Eva Kimby, Colm Bradley, Emili Montserrat
Publikováno v:
Haematologica, Vol 100, Iss 4 (2015)
We report the largest retrospective, phase IV non-interventional, observational study of ofatumumab therapy in heavily pre-treated patients with poor-prognosis chronic lymphocytic leukemia. Total number of patients was 103; median age was 65 years (r
Externí odkaz:
https://doaj.org/article/88e14d233e3641a9b138cf17d5691d9b
Autor:
Jan Molinský, Anna Panovská, Stanislava Hrobková, Heidi Mocikova, Marek Trněný, Josef Karban, Petra Obrtlikova, Michael Doubek, Lekaa Mohammadova, Martin Simkovic, Jan Novák, Martin Spacek, Lukas Smolej, Eduard Cmunt
Publikováno v:
Leukemia Research. 79:17-21
Chemoimmunotherapy with bendamustine and rituximab is an alternative treatment for elderly patients with CLL. The aim of this observational multicenter study was to prospectively assess efficacy and safety of bendamustine and rituximab in front-line
Autor:
Emília Flochová, Eva Mikuskova, Tomas Papajik, Michael Girschikofsky, Jiří Mayer, Liana Gercheva, Petra Altenhofer, Michael Steurer, Ulrich Jäger, Mikulas Hrubisko, August Zabernigg, Georgi Mihaylov, Lukas Smolej, Miriam Ladická, Lisa Pleyer, Sonja Burgstaller, Horst Oexle, Emil Spasov, Michael A. Fridrik, Richard Greil, Julian Raynov, Thomas Nösslinger, Eva Králiková, Olga Stehlíková, Alexander Egle, Cristina Burcoveanu, Martin Pecherstorfer, Thomas Melchardt, Anton Klingler, Stanislav Palasthy, Petra Obrtlikova, Michael Doubek, Tomas Kozak, Andreas L. Petzer, Johannes Andel
Publikováno v:
The Lancet Haematology. 3:e317-e329
Summary Background In many patients with chronic lymphocytic leukaemia requiring treatment, induction therapy with rituximab plus chemotherapy improves outcomes compared with chemotherapy alone. In this study we aimed to investigate the potential of
Autor:
Julian Raynov, August Zabernigg, Michael Girschikofsky, Richard Greil, Georgi Mihaylov, Teresa Magnes, Alexander Egle, Lukas Smolej, Eva Králiková, Olga Stehlíková, Liana Gercheva, Jiří Mayer, Lukas Weiss, Emil Spasov, Martin Pecherstorfer, Horst Oexle, Tomas Papajik, Daniela Voskova, Tomas Kozak, Stanislav Palasthy, Mikulas Hrubisko, Andreas L. Petzer, Petra Obrtlikova, Thomas Melchardt, Lisa Pleyer, Anton Klingler, Petra Altenhofer, Johannes Andel, Michael Doubek, Emília Flochová, Eva Mikuskova, Thomas Nösslinger, Miriam Ladická, Sonja Burgstaller, Michael Steurer, Ulrich Jäger, Christina Burcoveanu
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing induction
Autor:
Yvona Brychtová, Martin Trbušek, Lukas Smolej, Jitka Malčíková, Anna Panovská, Jana Chovancová, Jana Šmardová, Petra Obrtlikova, Ludmila Šebejová, Eva Jelinkova, Michael Doubek, Jakub Trizuljak, Markéta Hadrabová, Pavlína Volfová, Jiri Mayer, Denisa Bakesova, Šárka Pospíšilová, Josef Karban, Alexandra Oltová, Karla Plevová, Marek Mráz, Olga Stehlíková
Publikováno v:
American Journal of Hematology. 90:417-421
The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue. An important treatment option is the use of high-dose corticosteroids. The purpose of this clinical trial was to determine the efficacy and
Autor:
Šárka Pospíšilová, Eduard Cmunt, Marek Trněný, Lukas Smolej, Martin Brejcha, Zdeněk Pospíšil, Jiří Schwarz, Petr Kozmon, Jiří Mayer, Yvona Brychtová, Petra Obrtlikova, Michael Doubek
Publikováno v:
European Journal of Haematology. 87:130-137
Objectives: The impact of modern prognostic markers on clinical course of chronic lymphocytic leukemia (CLL) in everyday practice has been not yet well-defined, especially in large series of patients. Therefore, the goal of the present study was to a
Autor:
Petra Basova, Vojtech Kulvait, Šárka Pospíšilová, Josef Karban, Nikola Curik, Vit Pospisil, Emanuel Necas, Marek Mráz, Jiri Zavadil, Petra Obrtlikova, Tomas Stopka, Marek Trneny, Jiri Mayer, Karin Vargova, Filipp Savvulidi, Pavel Burda, Adela Berkova, Juraj Kokavec
Publikováno v:
Blood. 117:3816-3825
Elevated levels of microRNA miR-155 represent a candidate pathogenic factor in chronic B-lymphocytic leukemia (B-CLL). In this study, we present evidence that MYB (v-myb myeloblastosis viral oncogene homolog) is overexpressed in a subset of B-CLL pat
Autor:
Petra Obrtlikova, Renata Urbanova
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 28
Chemotherapy combinations with monoclonal antibodies are now the basis for treatment of chronic lymphocytic leukemia. Rituximab, the most widely used anti-CD20 antibody in routine clinical practice, led not only to improvement of progression-free sur
Publikováno v:
American Journal of Hematology